CD33 and acute myeloid leukemia: GO is an anti-CD33 antibody-drug conjugate, reimbursed for patients with newly diagnosed CD33+ AML who have a good or intermediate risk according to 2022 ELN risk stratification. The drug first received FDA approval in 2000 as monotherapy for elderly patients with AML, who were unfit for traditional chemotherapy.